Aprea Therapeutics, INC

Aprea Therapeutics reported Q2 2026 results, noting accelerated enrollment in its Phase 1 APR-1051 trial and early signs of clinical activity.

Aprea Therapeutics has received an additional 180-day period from Nasdaq to regain compliance with the minimum bid price requirement.

Aprea Therapeutics held its 2026 annual meeting, with stockholders approving key proposals including a reverse stock split authorization and director elections.

Aprea Therapeutics announced first quarter 2026 financial results, highlighting two partial responses in its APR-1051 trial and a $30 million oversubscribed private placement to fund ongoing development.

Aprea Therapeutics announced the closing of an oversubscribed $30 million private placement to fund the development of its lead oncology program, APR-1051.

Aprea Therapeutics announced fourth quarter and full year 2025 financial results, highlighted by early clinical proof-of-concept for its WEE1 inhibitor APR-1051 and a strengthened cash position.

Aprea Therapeutics reports continued net losses and cash burn, with funding expected to last into Q1 2028, while advancing its APR-1051 clinical program.

Aprea Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing financial results, ongoing clinical trials for APR-1051 and ATRN-119, and strategic updates.

Aprea Therapeutics reported significant losses and a dwindling cash balance, raising substantial doubt about its ability to continue as a going concern, despite ongoing clinical development.

Aprea Therapeutics reported a widened year-to-date net loss and a significant cash reduction, raising substantial doubt about its ability to continue as a going concern without additional funding.

Aprea Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Aprea Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Aprea Therapeutics, a clinical-stage precision oncology company, reported a net loss of $12.6 million for 2025 and warned of substantial doubt about its ability to continue as a going concern, alongside a Nasdaq minimum bid price deficiency.

Aprea Therapeutics' 10-K filing reveals significant losses and substantial doubt about its ability to continue as a going concern, despite ongoing Phase 1 clinical trials for its cancer therapeutics APR-1051 and ATRN-119.

Aprea Therapeutics' 10-K filing details its insider trading policy, outlining restrictions on trading while possessing material nonpublic information and other key guidelines.

Director Michael Grissinger received a grant of restricted stock units and stock options as part of his board compensation.

Director Gabriela Gruia was granted 3,135 restricted stock units and 12,555 stock options by Aprea Therapeutics.

Director Richard Peters received a grant of restricted stock units and stock options as part of annual board compensation.

Director John B. Henneman III was granted restricted stock units and stock options as part of board compensation.

Director Jean-Pierre Bizzari received a grant of restricted stock units and stock options as part of board compensation.

Director Marc Duey acquired 3,135 restricted stock units and 12,555 stock options as part of an annual compensation grant.

Aprea Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders on June 16, 2026, to vote on key proposals including a potential reverse stock split to maintain Nasdaq listing.

Aprea Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 5, 2025, with key proposals including the election of directors and ratification of the company's accounting firm.

Aprea Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on director elections, auditor ratification, executive compensation, and other matters.

Aprea Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, with key voting items including the election of directors and ratification of the company's accounting firm.

Aprea Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, covering director elections and auditor ratification.

Laurence W. Lytton has updated his beneficial ownership filing for Aprea Therapeutics, Inc., reporting a 3.2% stake.

Vestal Point Capital and Ryan Wilder have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Aprea Therapeutics, Inc.

AIGH Capital Management and Orin Hirschman have reported a combined beneficial ownership of 9.9% in Aprea Therapeutics, Inc., primarily through warrants and common stock.

Squadron Master Fund LP, along with its investment advisor Squadron Capital Management LLC and partners William Blank and Matthew Sesterhenn, has reported beneficial ownership of approximately 9.9% of Aprea Therapeutics, Inc. common stock.

Soleus Private Equity and affiliated entities, including Guy Levy, have disclosed a 9.99% beneficial ownership stake in Aprea Therapeutics, Inc. through warrants.

Nantahala Capital Management and its principals have reduced their beneficial ownership in Aprea Therapeutics, Inc. to 4.50% as of December 31, 2025.